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be made is that the long term survival of composite tissue grafts
will be dependant on the avoidance of chronic rejection.30
Only time and experience will tell us what is in store for us here.
Conclusion
There is much work still ongoing in the development of strategies
to counter transplant rejection in all areas of transplantation, and
possibly develop tolerance. There are still many areas in which
things can be improved. For example, the commonest cause for
loss of a renal transplant is death of the patient with a functioning
graft, at an age in advance of what would be predicted for a
healthy, age-matched individual32  Whilst part of this pathology
will reflect the impact of past renal disease and dialysis, 
the adverse effects of immunosuppressive drugs will also have
played a role. Reducing this pathology is a major focus within 
the transplant community today, and would greatly benefit 
recipients of all types of transplant.
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The mainstay of treatment for many diseases affecting the face and
mouth is still surgery.  However, like so many medical problems,
there are different techniques and nuances for treating these 
diseases and injuries.  A lot of these subtleties of approach are
steeped in history and have stood the test of time.  They are passed
from one generation of surgeons to the next with minor 
modifications that naturally follow on from our method of 
training, which is essentially an apprenticeship to surgical masters.  
These methods do achieve success in most cases otherwise they
would have been discarded long ago, but comparisons between
different techniques for the same condition in prospective 
randomised studies are sparse for many surgical groups. 
The commonest form of evidence provided to support particular
treatment protocols is the case series (level III).  It is still uncom-
mon to find level II (prospective randomised studies) or level I
(metanalyses). The consequence of this failure to compare 
different techniques is difficulty in adducing evidence which
defines best treatment for these conditions, especially where it
relates to more subtle parameters such aspost-operative pain 
experience, quality of life and complications.
The general public’s perception is that there are standard 
operations for all conditions, particularly the common ones such
as hernia repair, varicose vein elimination or wisdom tooth
removal. They believe that all surgeons carry out these operations
in the same manner.  They are shocked when they realise that 
surgeons may perform these operations very differently.
There are several reasons why surgical techniques are not 
compared in a prospective randomised fashion.  Some of these
relate to practical problems whilst others are more philosophical.
Firstly, prospective randomised studies demand scrupulous data
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collection and accurate data entry prior to considered statistical
analysis and publication.  The randomisation process is best 
carried out with the aid of an independent agency to avoid 
surgeon bias.  It is accepted that surgery is one of the busiest 
vocations and surgeons themselves are fully occupied with their
incredibly busy clinical workload, leaving no time for this 
data entry.
Secondly, with many disorders, no single surgeon or hospital unit
sees enough of these to conduct prospective randomised studies on
their own.  Collaboration between many units in multi-centre 
trials should therefore be the norm.  However, this is where we
come onto the third and fourth problems, which are more 
philosophical.  Surgeons must be confident in their skill and 
technique but the corollary of this is that they often disapprove of
techniques or protocols other than the one that they use. 
They believe that it is unethical to enter patients into a treatment
arm that they feel is less satisfactory than the one they currently
use, despite the fact that half the surgeons in the world may use the
technique they discard.  It is clearly not unethical to conduct these
prospective randomised studies but it does require surgeons to
accept that there is uncertainty and that their protocol of treatment
may not be the best on the market.  The classic example of 
surgeon  rigid refusal to contemplate alternative therapies was the
persistence with radical mastectomy and axillary clearance for
breast cancer throughout the Twentieth Century and the initial
scepticism and even ridicule heaped on those surgeons who had
the temerity to suggest that there might be alternative, less radical
treatments that achieved the same disease control with better 
quality of life for the patients.
Furthermore, surgeons, reputedly following the same protocol and
performing the same operation, may be doing it very differently
indeed.  This could invalidate inclusion of these different 
surgeons’ patients in the same treatment arm in a multi-centre
study. There are ways of achieving control over this problem, 
for example, through the histopathologist’s assessment of 
completeness of cancer resections.  Finally, research is not 
usually the surgeon’ major concern and they have more than
enough clinical work without trying to surmount these obstacles.
Oral and maxillofacial surgery, which deals with cancer affecting
large areas of the head and neck, facial injuries, facial deformity,
and facial pain, is, like so many other surgical specialties, beset by
these problems.  However, there is a large cohort of young, 
energetic surgeons who do wish to participate in prospective 
randomised studies but need the infrastructure to overcome these
hurdles.
The charity “The Facial Surgery Research Foundation - Saving
Faces” was founded in June 2000 with the express aim of setting
up a national clinical trials centre to provide this structure and deal
with these practical difficulties so enabling surgeons to participate
in prospective randomised studies.  The De Lotbiniere Facial
Surgery Research Centre, for which the foundation has now
secured funds, started work at the end of 2003 and is constituted
to provide this support. The model is that surgeons with research
ideas present these to a peer group who meet annually and vote on
the research proposals presented.  The top two research studies are
then presented to the research committee of the charity to assess
whether they are practically possible.  Following this, the research
centre director and clinical research manager will help the 
proposing surgeons draft ethical approval and project grant bids as
well as generating trial design and statistical methods.  Once these
steps have been completed the trial will be rolled out through the
participating group of surgeons, who will be supported locally by
research assistants.
When a suitable patient for inclusion in the trial presents to the
surgeon, they will inform the research assistant, who is employed
by the charity but works locally supporting participating surgeons
throughout the UK. The research assistant will be responsible for
explaining the trial to the patient in detail, encouraging their 
recruitment, contacting the trials centre for randomisation into
treatment arms and most importantly, for completing data entry
about the patient at the local site.  The research assistant will then
ensure that the patient is followed up closely and subsequent data
entry points are scrupulously maintained.  The trials centre is
responsible for bringing together all the data and regularly 
arranging for interim analyses by the trial steering committee and
a data-monitoring group prior to ultimate analysis and publication.
Studies have already been designed relating to oral cancer, 
tobacco disease prevention, safe alcohol consumption and facial
injuries.
The model, therefore, is of a charity (The Facial Surgery Research
Foundation - Saving Faces), raising funds to provide guaranteed
salaries for staff to run a national clinical trials centre (The De
Lotbiniere Facial Surgery Research Centre). They will obtain 
project grants and ethical approval for specific studies and 
supervise these studies through a network of locally appointed
research assistants co-located with and supporting surgeons
throughout the UK who are participating in the trials. 
The surgeons themselves (those who have not proposed and
designed the study) will simply ensure that all patients appropriate
for trial entry will be introduced to the locally based research
assistant who will ensure compliance with all aspects of the trial.
Those surgeons who propose trials will be intimately involved
with the trial design and its publication and will be the ultimate
authors of the latter.
Increasingly and not unreasonably, patients expect us to justify our
treatment protocols on the basis of hard evidence. In many 
situations, the only evidence we currently have available is the
case series. It is vital that we do clinical research using the best
available tool, the prospective randomised trial, to avoid bias and 
generate this evidence for “best treatment”. The Facial Surgery
Research Foundation - Saving Faces hopes to achieve this with its
new trials centre.
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